TALi Digital’s treatment for ADHD given major endorsement through key healthcare organisation
Health & Biotech
Health & Biotech
Link copied to
Special Report: Tali Digital’s push to be a global leader in digital therapeutics for the treatment of ADHD has been boosted with membership to the preeminent Digital Therapeutics Alliance.
TALi Digital Ltd (ASX: TD1) has cemented its position in the global digital therapeutics ecosystem, after being accepted as a member of the leading international organisation on digital therapeutics (DTx).
Founded in 2017, the Digital Therapeutics Alliance (DTA) is a non-profit trade association of industry leaders and stakeholders engaged in evidence-driven advancement of DTx products.
According to the DTA website DTx products work in a variety of ways, from calculating insulin doses to delivering cognitive behavioural therapy, and can help track and manage symptoms as well as improve medication adherence.
DTx products are often accessed through a smartphone or tablet and can be used independently or in concert with other treatments. The DTA provides patients, clinicians, payors and policymakers with tools necessary to evaluate and utilise DTx products.
TALi providing treatment hope for ADHD
TALi is a digital health company that delivers diagnostic and therapeutic solutions to enhance cognitive function and behaviour.
The company has built a patented platform technology targeting cognitive attention skills during early childhood via its game-based screening (DETECT) and training (TRAIN) modules.
The company has had several successes in recent months in its goal to be a global leader in treating ADHD and related conditions through DTx products.
TALi recently signed a strategic licencing agreement with Akili Interactive for the United States market, with the two companies establishing a clinical development program.
A process to deliver a submission for US FDA marketing approval has also been initiated as per the agreement. Akili is expected to make its first co-development payment to TALi during January – March 2022.
At the end of Q1FY2022 TALi were in a strong financial position with a cash balance of $2.2m to fund future growth. Furthermore, Invest Victoria granted TALi a $500k funding facility as part of the Victorian Government’s R&D Cash Flow Loan Initiative, ensuring the company can continue its commercialisation objectives.
TALI will be showcased by the DTA in its product library and is one of only a handful of digital DTx products with evidence-based and in-market solutions recognised by global regulators.
TALi managing director and CEO Glenn Smith said being accepted as a DTA member was an important vote of confidence in the company’s DTx products.
“TALi is pleased to join this preeminent global organisation where members are regarded as industry thought leaders in healthcare worldwide,” Smith said.
“The showcase of TALi combined with our membership of the DTA will only serve to assist our goal of executing additional partnerships in various jurisdictions to ensure the commercialisation success for TALi.”
This article was developed in collaboration with TALi Digital, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.